Cutler Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Cutler Group’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9,000	Closed	-$10K	–	5745
2022 Q2	$10K	Buy	+9,000	New	+$141K	﹤0.01%	3240
2016 Q4	–	Sell	-2,340	Closed	-$8K	–	7534
2016 Q3	$8K	Buy	+2,340	New	+$165K	﹤0.01%	4507
2016 Q2	–	Sell	-1,860	Closed	-$4K	–	7478
2016 Q1	$4K	Sell	1,860 -20	-1%	-$1.62K	﹤0.01%	5128
2015 Q4	$19K	Buy	+1,880	New	+$255K	﹤0.01%	3487

Cutler Group's KDNY Position: Q3 2023 in Review

Cutler Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 2,700 shares — an estimated $103K sold.

Cutler Group first reported a position in KDNY in Q1 2016 and held it in 20 quarters. The position peaked at $184K in Q1 2016. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Cutler Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Cutler Group sold 2,700 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $103K.
Cutler Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2016 and held it in 20 quarters.
Cutler Group's Chinook Therapeutics, Inc. Common Stock position peaked at $184K in Q1 2016.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.